Our Current Lead Programs

Through our research efforts we have evaluated over 100+ compounds for their serotonin receptor binding profiles via 5-HTome, the majority of which can be categorized in two broad drug development programs: 1) 5-HT2A agonist program with low 5-HT2B liability, and 2) 5-HT2C selective program with low 5-HT2A and 5-HT2B liability.


5-HT2A receptor agonist exhibiting multi-receptor selectivity

  • Inactive at 5-HT2B receptor
  • Non-hallucinogenic
  • Therapeutic indications: treatment-resistant depression (TRD); PTSD

Selective 5-HT2C receptor agonist

  • Low Activity/Inactivity at 5HT1A, 5-HT2A and 5-HT2B receptors
  • Non-hallucinogenic
  • Therapeutic indications: schizophrenia; Alzheimer’s-induced psychosis; eating disorders